Liberate Physician Center - Southwest Florida

06/16/2026

Medical Ma*****na reclassified

🚨The United States just offically recliassified cannabis.

The federal reclassification of medical ma*****na to Schedule III marks a monumental shift in U.S. drug policy, promising to unlock clinical research and deliver massive tax relief to state-legal businesses.

After more than half a century under the nation's most restrictive drug category, state-licensed medical ma*****na has been officially reclassified from Schedule I to Schedule III by the federal government.

Since 1970, cannabis was grouped alongside he**in and L*D under the assumption that it had high abuse potential and no accepted medical value—a designation that increasingly clashed with the reality of millions of Americans legalizing its use under state programs.

While the change does not legalize recreational ma*****na federally or allow interstate sales, it removes significant roadblocks for medical cannabis operators and scientists alike.

The practical implications of this policy shift are vast, particularly for the business and scientific communities.

State-licensed medical dispensaries can finally access standard federal tax deductions and operate with fewer restrictions, while clinical researchers can now bypass long-standing bureaucratic hurdles to conduct comprehensive studies on the drug's medical efficacy and long-term health risks. Proponents hail the reclassification as a long-overdue, science-based correction, whereas critics warn it could downplay the potential risks associated with heavy cannabis use.

source: NBC News. Cannabis reclassification could 'open the floodgates' for research, scientists say.

06/08/2026

Medical cannabis and travel

The Transportation Security Administration (TSA) has updated its guidance on traveling with medical ma*****na, adding information to its "What Can I Bring?" directory for carry-on and checked baggage. 🔗⬇️

04/27/2026

Trump Says Medical Ma*****na Is ‘The Best Of All The Alternatives’ For People Suffering With Illnesses
President Donald Trump highlighted the medical benefits of ma*****na on Thursday, hours after the Department of Justice announced it is moving ahead with a cannabis rescheduling proposal.
“A lot of people are suffering from big problems, which this seems to be the best answer,” the president said in the Oval Office. “They’re very happy about it. So the rescheduling is starting, and that’s a big thing, rescheduling. They kept saying, ‘what about the rescheduling.'”
Trump noted that his administration’s actions on cannabis rescheduling came after his friend Howard Kessler told him about how he used medical ma*****na.
“He had some medical difficulties, and he came upon this by accident, in a way,” the president said. “He had to go through a lot of different medications, and he said this was the one that was much better than anything else. And so he experienced that. He didn’t benefit by it, other than from the standpoint that he lives a much better life now.”
“So hopefully you don’t need it,” he said. “But if you do need it, I hear it’s the best of all the alternatives.”

*****na

04/27/2026

THE ECS is not the same in men and women.

Recent research is shedding light on the critical, often overlooked reality that the endocannabinoid system (ECS) is s*xually dimorphic. From how our bodies process cannabinoids to differences in pain modulation, metabolism, and stress response, s*x is a fundamental biological variable that influences ECS function.

Why does this matter?
Whether in clinical research, drug development, or patient care, a "one-size-fits-all" approach to cannabinoid-based therapies may be missing the mark.
For instance:
➡️ Pain Management: Males and females often show distinct responses to cannabinoid analgesia, influenced by different metabolic enzyme levels.
➡️ Metabolism: Due to differences in body composition and hormonal regulation of CB1 receptors, THC absorption and clearance rates can vary significantly between the s*xes.
➡️ Anxiety & Stress: Hormonal fluctuations, such as those during the menstrual cycle, can shift how the ECS responds to stress and exogenous cannabinoids.
*****na

04/24/2026

“The DOJ action today to reschedule medical ma*****na offers hope for long-overdue research and funding to unlock the science behind the medicinal benefits of cannabis”. Daniel Reid, Founder of Liberate

The Trump administration is officially moving ahead with the federal reclassification of ma*****na. More than four months after President Donald Trump signed an executive order directing the Department of Justice to expeditiously finish the process of moving cannabis from Schedule I to Schedule III....

03/20/2026

Cannabis Compounds CBD and CBG May Help Treat Fatty Liver Disease Affecting One-Third of Adults Worldwide

Recent research indicates that certain non-psychoactive compounds from the cannabis plant show promising potential in addressing fatty liver disease, also known as metabolic dysfunction-associated steatotic liver disease (MASLD).

This condition, affecting a large portion of adults worldwide, involves excessive fat accumulation in the liver, often linked to obesity, insulin resistance, and metabolic issues, with limited approved treatments beyond lifestyle changes.

The key compounds investigated are cannabidiol (CBD) and cannabigerol (CBG), both lacking the intoxicating effects of THC.

In preclinical experiments using obese mice fed high-fat diets to induce liver fat buildup, treatment with these compounds over four weeks significantly reduced hepatic triglycerides (liver fat), normalized blood lipid profiles, and improved glycemic control by enhancing insulin sensitivity and glucose clearance.

CBG demonstrated particularly strong effects, more robustly lowering body fat mass, "bad" LDL cholesterol, and overall metabolic markers compared to CBD. The beneficial outcomes appear to stem from mechanisms independent of classical cannabinoid receptors.

Instead, the compounds promote metabolic remodeling in the liver, boosting phosphocreatine-based energy buffering as a backup system and restoring lysosomal function for better cellular cleanup and waste removal.

This dual action helps the liver better handle lipids, reduce harmful accumulation, and combat inflammation and oxidative stress tied to disease progression.

While these findings highlight CBD and CBG as exciting, plant-derived candidates for future therapies, the evidence remains preclinical—primarily from animal models—and human clinical trials are still needed to confirm safety, optimal dosing, efficacy, and long-term impacts in people.

————————————————————

A Potential New Plant Based Treatment Path

Although the results are promising, the researchers emphasize that further studies are needed to determine how these findings may translate to human treatments. Additional research will help clarify whether these compounds could eventually be developed into therapies.

Still, the study highlights an emerging direction in metabolic disease research. By targeting how cells store energy and clear waste, plant derived compounds such as CBD and CBG may open new possibilities for treating fatty liver disease and related metabolic disorders.

Links:
https://lnkd.in/gpD2cnva

https://lnkd.in/gt6sD9Hj

https://lnkd.in/g7WN3anX

Source: Hebrew University of Jerusalem, British Journal of Pharmacology

03/18/2026

Chronic back pain is one of those conditions that settles in and shapes a patient’s life from the moment they wake up. Muscles clamp down, nerves stay irritated, and inflammation becomes the background noise the body cannot quite turn off.

When cannabinoids step in for this type of pain, they are not acting as simple painkillers. They are helping the ECS, our Master Regulator, regain control over the signaling loops that drive persistent discomfort.

A clear example comes from the study "Cannabinoid Receptor Agonists and Antagonists as Analgesics" (2020), which showed how cannabinoids influence pain transmission through both the CB1 and CB2 pathways. That work helped clarify why THC shifts the perception of pain while CBD, CBGa, and CBDa influence the chemical landscape that keeps nerves inflamed.

THC helps turn down the volume on those amplified nerve messages that travel from irritated spinal tissue to the brain. CBD and CBGa help the body regulate inflammatory processes that wrap tightly around the spine and create muscle guarding. When those tissues settle down, the nerves stop firing the same distress signal on a loop.

CBDa supports this from another angle by influencing inflammatory pathways that run through the soft tissues and joint structures of the back. The acids give the Master Regulator room to reorganize the pain response so the body stops chasing itself in circles.

Mobility improves, tension drops, and the patient feels a return of internal steadiness instead of the familiar burn that pushes them into fatigue.

Every patient is different. Some rely on THC for function, while others stabilize with morning CBGa. What matters is that cannabinoids give the Master Regulator the tools it needs to reshape how pain signals flow.

When the system can do its job, the relief feels natural, not forced, and chronic back pain loses the grip it held for far too long.

Credit-Mike Robinson, Founder Global Cannabinoid Research Center (GCRC)

03/12/2026

🧠 Why is cannabis overdose considered extremely unlikely?

The answer lies in the brain.

The brainstem, which controls breathing and cardiovascular function, contains very few CB1 cannabinoid receptors. Because cannabinoids interact primarily with these receptors, they do not significantly suppress respiration.

In contrast, opioids act on receptors that are highly concentrated in the brainstem, which is why opioid overdose can stop breathing.

🌿 This difference in receptor distribution is a key reason why fatal overdose from cannabis alone has not been documented in scientific literature.
Understanding the endocannabinoid system helps clinicians better evaluate both the safety and therapeutic potential of cannabinoids.

03/06/2026

Need to research this... sounds promising!

Breakthrough research shows cannabis compounds like THC can clear toxic proteins linked to Alzheimer's disease from brain cells.

Researchers at the Salk Institute and Scripps Research Institute have identified compelling evidence that tetrahydrocannabinol (THC) and other cannabinoids can target the root causes of Alzheimer's disease. Laboratory tests on human nerve cells revealed that these compounds help remove amyloid-beta, a toxic protein that forms plaques and triggers damaging brain inflammation. By activating the body’s natural endocannabinoid system, these substances not only promoted the clearance of these harmful proteins but also inhibited the enzymes responsible for plaque production, effectively slowing the cellular damage associated with the disease.

While these findings highlight a significant neuroprotective potential for combined THC and CBD therapies, experts emphasize that the research is still in preliminary stages. Most successes have occurred within controlled laboratory environments and animal models, and rigorous human clinical trials are required to determine if these results translate to real-world medical benefits. Currently, there is no evidence that cannabis can cure or reverse dementia, but this exploratory work provides a vital roadmap for developing future treatments aimed at protecting the brain from inflammatory decay.

source: Salk Institute for Biological Studies. Cannabinoids remove plaque-forming Alzheimer's proteins from nerve cells. Nature: Aging and Mechanisms of Disease.

02/24/2026

Cannabis and legalization initiative.

A Florida campaign seeking to put ma*****na legalization on the ballot is facing another complication as it continues to litigate the status of its 2026 signature drive. Under a new election law, the hundreds of thousands of signatures activists already collected for this year will not be carried ov...